Disclosed positions

Estimated from their latest filings — positions may have changed since

$438.6K

combined est. value

Stock	Shares	Price	Value	Weight	As of
LYELLyell Immunopharma, Inc.	15,306	$15.91	$243.5K	56%	2025-08-21
KROSKeros Therapeutics, Inc.	12,665	$11.65	$147.5K	34%	2026-06-11
CHRSCoherus Oncology, Inc.	30,000	$1.59	$47.5K	11%	2026-06-05

LYEL

Lyell Immunopharma, Inc.

$243.5K

15,306 sh

KROS

Keros Therapeutics, Inc.

$147.5K

12,665 sh

CHRS

Coherus Oncology, Inc.

$47.5K

30,000 sh

All filings on record

Every Form 4 transaction we track for this filer

all 6buys 0sells 4

Stock	Transaction	Date	~6mo later
KROSKeros Therapeutics, Inc.	Sell $5.5K · 550 sh	2026-06-11	—
CHRSCoherus Oncology, Inc.	Grant — · 30,000 sh	2026-06-05	—
LYELLyell Immunopharma, Inc.	Sell $15.3K · 1,453 sh	2025-08-21	—
LYELLyell Immunopharma, Inc.	Grant — · 8,000 sh	2025-08-20	—
LYELLyell Immunopharma, Inc.	Sell $1.4K · 136 sh	2025-08-12	—
LYELLyell Immunopharma, Inc.	Sell $1.4K · 131 sh	2025-08-11	—

KROSSell

2026-06-11 · Keros Therapeutics, Inc.

$5.5K

—

CHRSGrant

2026-06-05 · Coherus Oncology, Inc.

30,000

—

LYELSell

2025-08-21 · Lyell Immunopharma, Inc.

$15.3K

—

LYELGrant

2025-08-20 · Lyell Immunopharma, Inc.

8,000

—

LYELSell

2025-08-12 · Lyell Immunopharma, Inc.

$1.4K

—

LYELSell

2025-08-11 · Lyell Immunopharma, Inc.

$1.4K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.